<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040074</url>
  </required_header>
  <id_info>
    <org_study_id>VRP01-001</org_study_id>
    <nct_id>NCT05040074</nct_id>
  </id_info>
  <brief_title>SQ-Kyrin TMVr FIM Study</brief_title>
  <official_title>SQ-Kyrin Transcatheter Mitral Valve Repair System Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Shenqi Medical Technology Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Shenqi Medical Technology Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A feasibility study to evaluate the effectiveness and safety of the SQ-Kyrin Transcatheter&#xD;
      Edge-to-Edge Valve Repair System for the treatment of moderate-to-severe mitral regurgitation&#xD;
      in patients with high surgical risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-arm observation, feasibility clinical study that&#xD;
      plans to enroll a total of not less than 10 and not more than 30 patients, adopts the post-op&#xD;
      immediate technical success rate as the primary endpoint, and uses the all-cause mortality at&#xD;
      30 days post-op, incidence of serious adverse event at 30 days post-op, device success rate&#xD;
      at 30 days post-op, and procedural success rate at 30 days post-op as secondary endpoints to&#xD;
      evaluate the effectiveness, safety, and feasibility of the Transcatheter Edge-to-Edge Valve&#xD;
      Repair System of Shanghai Shenqi Medical Technology Co., Ltd. in clinical use and&#xD;
      preliminarily evaluate the product's performance. A phasic study report (for phasic data&#xD;
      summary and analysis) will be issued after completion of the 30-day postoperative follow-up&#xD;
      to evaluate the effectiveness, safety, and feasibility of the device and apply for clinical&#xD;
      studies before official registration and marketing. In the meantime, patients enrolled will&#xD;
      continue to be followed up for 6 months and 1-5 years post-op to evaluate the long-term&#xD;
      effect of the mitral valve repair system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of acute procedural success</measure>
    <time_frame>Immediate postoperative</time_frame>
    <description>Must meet all the four items：1）no procedural mortality; 2）success in delivery and retrieval of the device delivery system; 3）successful deployment and accurate positioning of the device; 4）no emergency surgery or reintervention related to the device or surgical approach</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse event(SAE)</measure>
    <time_frame>1 month</time_frame>
    <description>If the adverse event meets any of the criteria below, it is regarded as a serious adverse event (SAE): 1) results in death; 2) is life threatening, results in illness or injury; 3) requires inpatient hospitalization or prolongation of existing hospitalization; 4) results in a persistent or significant disability/incapacity; 5) results in a congenital anomaly/birth defect, fetal death, fetal distress; 6) results in medical or surgical intervention to prevent permanent impairment to body structure or a body function; 7) an important medical event that may not result in death, be life-threatening, or require hospitalization but may be considered serious when, based upon appropriate medical judgment, may jeopardize the patient or subject and/or may require intervention to prevent one of the outcomes listed in this definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success rate</measure>
    <time_frame>1 month</time_frame>
    <description>Definition of device success（must meet all the four items） ：1) No procedural mortality or stroke；2) Proper deployment and positioning of the device；3) No emergency surgery or reintervention related to the device or surgical approach；4) The implanted mitral valve repair system achieves the following safety and effectiveness indicators:&#xD;
No evidence of structural or functional abnormality&#xD;
No device-related technical failure or complication&#xD;
Significant functional improvement after valve repair, without significant stenosis (post-op EOA ≥ 1.5 cm2 and transvalvular pressure gradient &lt; 5 mmHg/valve regurgitation ≤ Grade 2+/no device-related hemolysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success rate</measure>
    <time_frame>1 month</time_frame>
    <description>Definition of procedural success（must meet the two items）：1) Device success；2) Absence of the following severe complications: death; stroke; life-threatening hemorrhage; severe vascular complications; secondary severe organic heart diseases (e.g.: aortic dissection, left atrium/auricle rupture, left ventricular outflow tract obstruction, etc.); Grade II-III and above renal insufficiency; myocardial infarction or coronary ischemia requiring percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG); severe hypotension, heart failure, respiratory failure requiring use of high-dose vasoactive medications/mechanical acids; any valve-related dysfunctions, including repair device detachment (single or two valve leaflets)/embolism/device-related autologous mitral valve damage/other conditions requiring second intervention.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>SQ-Kyrin TMVr Feasibility Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental group is allocated to use the transcatheter edge-to-edge valve repair system of Shanghai Shenqi Medical Technology Co., Ltd.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System</intervention_name>
    <description>Transesophageal echocardiography-guided, implantable mitral valve clip repair system</description>
    <arm_group_label>SQ-Kyrin TMVr Feasibility Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Severe mitral valve regurgitation ≥ 3+ (moderate-to-severe mitral regurgitation&#xD;
             disease);&#xD;
&#xD;
          2. Patients with high or prohibitive risk for conventional open thoracic surgery as&#xD;
             defined by STS risk scoring result; subjects who are judged as not tolerating mitral&#xD;
             valve surgery due to STS procedural mortality risk ≥ 8% for mitral valve replacement&#xD;
             or presence of any of the following risk factors:&#xD;
&#xD;
               1. Porcelain aorta or active ascending aortic atheroma&#xD;
&#xD;
               2. Prior radiation therapy to mediastinum&#xD;
&#xD;
               3. History of mediastinitis&#xD;
&#xD;
               4. Left ventricular ejection fraction (LVEF) &lt; 40%&#xD;
&#xD;
               5. Presence of unobstructed coronary artery bypass graft&#xD;
&#xD;
               6. History of 2 or more cardiothoracic surgeries&#xD;
&#xD;
               7. Liver cirrhosis&#xD;
&#xD;
               8. Other surgical risk factors&#xD;
&#xD;
          3. Degenerated MR patients, or functional MR patients who have received&#xD;
             guideline-directed medical therapy (GDMT therapy)&#xD;
&#xD;
          4. Age ≥ 18 years, male or female;&#xD;
&#xD;
          5. Patients who are at extremely high risk or not suitable for conventional mitral valve&#xD;
             surgery, as assessed by a multidisciplinary heart team (including at least one cardiac&#xD;
             surgeon and one cardiologist);&#xD;
&#xD;
          6. Anatomically suitable for transcatheter mitral valve repair by edge-to-edge technique&#xD;
             and can be treated by the SQ-Kyrin device;&#xD;
&#xD;
          7. Patients who can understand the objectives of the trial, volunteer to participate in&#xD;
             the study, sign the informed consent form, and are willing to receive related&#xD;
             examinations and clinical follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of cardiac and mitral valve surgeries;&#xD;
&#xD;
          2. Infective endocarditis or evidence of active infection;&#xD;
&#xD;
          3. Mitral valve stenosis;&#xD;
&#xD;
          4. Severe uncontrolled coronary artery disease;&#xD;
&#xD;
          5. Pulmonary artery hypertension (systolic pulmonary artery pressure &gt; 70 mmHg);&#xD;
&#xD;
          6. Severe right cardiac insufficiency;&#xD;
&#xD;
          7. LVEF &lt; 30%;&#xD;
&#xD;
          8. Cardiac function of NYHA Class IV;&#xD;
&#xD;
          9. Patient is extremely week to tolerate surgery under general anesthesia, or in a shock&#xD;
             state indicating circulatory support;&#xD;
&#xD;
         10. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis;&#xD;
&#xD;
         11. Chronic dialysis;&#xD;
&#xD;
         12. Definite coagulation disorder and severe coagulation system diseases;&#xD;
&#xD;
         13. Clear contraindications for use of anticoagulants;&#xD;
&#xD;
         14. Cerebral stroke or transient ischemic attack in the past 30 days;&#xD;
&#xD;
         15. Any cardiac mass, left ventricular or atrial thrombosis identified by&#xD;
             echocardiography;&#xD;
&#xD;
         16. Other valve diseases that requiring surgery or intervention;&#xD;
&#xD;
         17. Severe macrovascular disease requiring surgical treatment;&#xD;
&#xD;
         18. Treatment-naive carotid artery stenosis &gt; 70%;&#xD;
&#xD;
         19. Imaging evidence of inappropriate cardiac and valve anatomy;&#xD;
&#xD;
         20. Known hypersensitivity to contrast media, and nickel-titanium memory alloy products;&#xD;
&#xD;
         21. Severe nervous system disorder compromising the cognitive ability;&#xD;
&#xD;
         22. Life expectancy &lt; 12 months;&#xD;
&#xD;
         23. Severe thorax deformity;&#xD;
&#xD;
         24. Pregnant and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Grace Gu</last_name>
    <phone>13636491192</phone>
    <email>guchaojun@sqmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital of Northern Theater Command, PLA</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>123005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaling Han, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Regurgitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT05040074/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

